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Tumor Necrosis Factor System Activity Is
Associated With Insulin Resistance and
Dyslipidemia in Myotonic Dystrophy
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Roser Casamitjana, Joan Vendrell, Joan Soler, and José Manuel Gómez-Sáez
Myotonic dystrophy (MyD) is a multisystem autosomal
dominant disorder associated with progressive muscle
wasting and weakness. The striking metabolic abnor-
mality in MyD is insulin resistance. The mechanism by
which target tissues are insensitive to insulin action
remains uncertain. In a recent study, plasma soluble
tumor necrosis factor receptor (sTNFR)2 levels were
found to be associated with muscle tissue mass and
insulin resistance. Given these associations, we specu-
lated that disorders of the muscle cell membrane could
lead simultaneously to insulin insensitivity and
sTNFR2 leakage in MyD. To test this hypothesis, we
measured the levels of circulating sTNFR1 and sTNFR2
and insulin resistance in MyD patients. We studied 22
MyD patients and 24 age-, BMI-, and fat mass–matched
control subjects. Both MyD men and women showed
higher plasma insulin levels in the presence of compa-
rable glucose concentrations than did control subjects.
sTNFR2, but not sTNFR1, levels were ~1.5-fold higher
in MyD patients. In parallel with these findings, the
fasting insulin resistance index (FIRI) was also higher
in MyD patients. In fact, in the whole population, fast-
ing insulin and FIRI strongly correlated with sTNFR2 in
both men (r = 0.77 and r = 0.81, P < 0.0001, respectively)
and women (r = 0.67 and r = 0.64, P = 0.001, respec-
tively). sTNFR2 levels were also associated with the
insulin sensitivity index (SI), calculated from an oral
glucose tolerance test (OGTT) according to the method
by Cederholm and Wibell (r = –0.43, P = 0.006). We con-
structed a multiple linear regression to predict FIRI,
with BMI, waist-to-hip ratio, and sTNFR2 as indepen-
dent variables. In this model, both BMI (P = 0.0014) and
sTNFR2 (P = 0.0048) levels contributed independently
to 46% of the variance of FIRI. In another model, in
which FIRI was substituted for SI from the OGTT, both
BMI (P = 0.0001) and sTNFR2 (P = 0.04) levels con-
tributed independently to 48% of the variance of SI
from the OGTT. Plasma cholesterol and triglyceride
concentrations were significantly increased in MyD
patients. sTNFR1 and sTNFR2 levels were found to be
strongly associated with plasma cholesterol, LDL 
cholesterol, and triglycerides. sTNFR1 and sTNFR2
also correlated with serum creatine kinase activity in 
MyD patients (r = 0.57, P = 0.006; r = 0.75, P < 0.0001,
respectively). In conclusion, here we describe, for the
first time to our knowledge, a relationship between
insulin action and plasma sTNFR2 concentration in
MyD patients. We have also found increased concen-
trations of plasma triglycerides and cholesterol levels
in parallel with sTNFR1 and sTNFR2 concentrations in
MyD patients. We speculate that the latter associations
are dependent on, and secondary to, increased tumor
necrosis factor (TNF)-a action. Whether TNF action is
implicated in the pathogenesis of MyD or is a simple
marker of disease activity awaits further studies. 
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M
yotonic dystrophy (MyD) is a multisystem
autosomal dominant disorder associated with
progressive muscle wasting and weakness.
The onset of symptoms typically occurs in the
2nd and 3rd decades of life. MyD is the most common adult
form of muscular dystrophy, with an estimated prevalence of
1 in 8,000 (1). The MyD gene has been identified as an expan-
sion mutation of a trinucleotide repeat at chromosome
region 19q 13.3 (2). The gene product is a protein kinase
(PK) of metabolic importance to muscle.
The striking metabolic abnormality in MyD is insulin resis-
tance. Marked hyperinsulinemia after oral glucose, intra-
venous glucose, tolbutamide, glucagon, or arginine tolerance
tests is observed in MyD patients (3,4). The mechanism by
which target tissues are insensitive to insulin action remains
uncertain, although a receptor or postreceptor defect has
been suggested (3,4).
In recent years, it has been demonstrated that tumor
necrosis factor (TNF)-a has important effects on whole-body
lipid and glucose metabolism (5,6). TNF-a is a candidate
mediator of insulin resistance because it is overexpressed in
the adipose and muscle tissues of rodents and humans and
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blocks the action of insulin in cultured cells and whole ani-
mals (7–9). The induction of insulin resistance is mediated
through TNF-a’s ability to produce serine phosphorylation of
insulin receptor substrate-1, decreasing the tyrosine kinase
activity of the insulin receptor (10).
TNF signals through at least two known cell surface recep-
tors (TNFRs), TNFR1 (p55) and TNFR2 (p75), that are pres-
ent in virtually all cells of higher mammals (11–13). It appears
that TNFR1 can signal for virtually all known activities of TNF,
including apoptosis, differentiation, and proliferation.
TNFR2 seems to signal metabolic actions (13). Both receptors
for TNF exist also in soluble forms (14,15), apparently
derived by proteolytic cleavage from the cell surface forms
(16). These soluble TNFRs (sTNFRs) can compete with the
cell surface receptors and thus block their activity. However,
sTNFRs affect TNF function also by stabilizing TNF activity,
most likely by preventing dissociation of the homotrimeric
TNF molecules to inactive monomers (16). It has been sug-
gested that sTNFR1 and sTNFR2 represent markers of pre-
vious TNF-a activity by forming a “slow release reservoir” and
impeding spontaneous denaturation of the cytokine, remain-
ing elevated for several days after TNF-a administration (16).
In a recent study, obese women expressed approximately
twofold more TNFR2 mRNA in fat tissue and approximately
sixfold more sTNFR2 in circulation relative to lean control
subjects (17). Adipose tissue TNFR2 expression strongly cor-
related with BMI and the level of insulinemia. We have
recently found that plasma sTNFR2 levels were inversely
associated with insulin sensitivity in healthy subjects (18). Fur-
thermore, sTNFR2 levels correlated positively with parame-
ters of the muscle compartment, such as fat-free mass, mid-
arm muscle circumference, and mid-arm muscle area (18). In
contrast, no correlation was observed between any meta-
bolic variable and adipose tissue TNFR1 expression (17) or
plasma sTNFR1 levels (18).
Muscle fibers displayed enhanced expression of TNF-a, and
upregulation of cytokines was strongest at sites of cellular
i n filtration, typical for the respective myositis subtype in two
recent studies dealing with inflammatory myopathies (19,20).
U n f o r t u n a t e l y, MyD patients were not included in these
reports. We are unaware of any study investigating TNF
expression or TNF action in MyD. Given the associations
between sTNFR2 levels and the muscle compartment, we
speculated that disorders of the muscle cell membrane
could lead simultaneously to insulin insensitivity and
sTNFR2 leakage. To test this hypothesis, we measured the
levels of circulating sTNFR1 and sTNFR2 and insulin resis-
tance in MyD patients.
RESEARCH DESIGN AND METHODS
S u b j e c t s . We studied 22 MyD patients and 24 control subjects who were similar
in age, BMI, and fat mass (Table 1). Characteristics of the subjects are summa-
rized in Table 1. MyD diagnosis was based on clinical measures and on evidence
of CTG repeats in the 39-untranslated region of the gene involved in MyD patho-
genesis. Inclusion criteria for patients and subjects included 1) BMI (weight in kilo-
grams divided by the square of height in meters) < 40 kg/m2; 2) absence of any
systemic disease other than MyD; and 3) absence of any infections in the previ-
ous month. None of the subjects were taking any medication known to interfere
with glucose or lipid metabolism or had any evidence of metabolic disease other
than obesity. All reported that their body weight had been stable for at least 3
months before the study. Metabolic and hormonal data on some of the subjects
were reported previously (18). The protocol was approved by the hospital ethics
committee, and informed consent was obtained from each subject.
Anthropometric measurement. All subjects were evaluated, in addition to
BMI, through the waist-to-hip ratio (WHR), as previously described (18). The per-
centage of body fat and fat-free mass were measured by bioelectric impedance
analysis (Holtain BC Analyser, London, U.K.).
Study protocol. An oral glucose tolerance test (OGTT) was performed according
to the recommendations of the National Diabetes Data Group (21). After a 
12-h overnight fast, glucose was ingested in a dose of 75 g, and blood samples were
collected through a venous catheter from an antecubital vein at 0, 30, 60, 90, and
120 min for measurement of serum glucose. The glucose (mean blood glucose
[MBG]) and insulin (mean serum insulin [MSI]) total areas under the curve during
the OGTT were determined by the trapezoidal method. The degree of peripheral sen-
sitivity to insulin was estimated during the OGTT according to the method validated
by Cederholm and Wibell (22). In this method, as in the minimal model developed
by Bergman et al. (23), the glucose-insulin homeostatic system is considered to be
divided into two parts, pancreatic responsiveness and peripheral cell responsive-
ness, permitting analysis of each part by input and output observations without dis-
rupting the glucose-insulin feedback relationship (22). The glucose uptake rate in
peripheral target tissues (M) is expressed as milligrams per minute and is calculated
according to the following formula: M = OGL/120 + [(G0 – G1 2 0) 3 0.19 3 B W ] / 1 2 0 ,
where OGL is the oral glucose load (75,000 mg), which was used as a constant fac-
tor; G0 – G1 2 0 is the amount of glucose at the fasting level minus the amount at 120
min, representing the part of the OGL left in the glucose space after 2 h; and BW is
the body weight in kilograms. The factor 120 converted 2 h into minutes. When the
glucose uptake rate is evaluated during clamp tests, it is usually expressed as the
metabolic clearance rate (MCR) to avoid the influence of different blood glucose
levels on the uptake rate. For the purpose of assessing the insulin sensitivity index
TABLE 1
Anthropometric and biochemical variables
MyD men Control men P v a l u e MyD women Control women P v a l u e
n 8 1 1 — 1 4 1 3 —
Age (years) 38.5 ± 9.6 39.1 ± 6.7 N S 38.7 ± 5.9 42.3 ± 10 N S
BMI (kg/m2) 26.8 ± 2.2 26.9 ± 3.7 N S 32.9 ± 2.2 32.5 ± 2.7 N S
W H R 0.98 ± 0.2 0.94 ± 0.3 N S 0.89 ± 0.3 0.91 ± 0.4 N S
Fat mass (kg) 23.1 ± 9.6 19.1 ± 9.57 N S 22.2 ± 10 26.9 ± 12.4 N S
Percent fat mass (%) 30.6 ± 12.3 21.9 ± 9.5 N S 28.6 ± 10.2 33.5 ± 11.1 N S
sTNFR1 (ng/ml) 2.1 ± 0.8 1.61 ± 0.14 N S 1.81 ± 0.7 1.45 ± 0.26 0 . 0 8
sNTFR2 (ng/ml) 4.51 ± 1.6 3.06 ± 0.2 0 . 0 4 3.91 ± 1.17 2.62 ± 0.28 0 . 0 0 1
Fasting glucose (mmol/l) 5.27 ± 0.49 5.45 ± 0.53 N S 5.41 ± 0.9 5.38 ± 1.3 N S
Fasting insulin (mU/l) 15.4 ± 8 8.7 ± 3.1 0 . 0 2 1 20.7 ± 11 9.9 ± 5.4 0 . 0 0 3
F I R I 3.2 ± 1.34 1.94 ± 0.86 0 . 0 3 1 4.7 ± 2.5 2.16 ± 1.3 0 . 0 0 3
Cholesterol (mmol/l) 5.91 ± 0.8 5.24 ± 0.75 0 . 0 8 5.6 ± 0.8 5.25 ± 0.8 N S
LDL cholesterol (mmol) 4.6 ± 0.6 3.8 ± 0.7 0 . 0 5 4.3 ± 0.5 3.6 ± 0.8 0 . 0 1 9
Triglycerides (mmol/l) 2.03 ± 0.4 1.19 ± 0.4 0 . 0 0 1 2.41 ± 0.37 1.33 ± 0.8 0 . 0 0 1
Data are means ± SD or n.
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(SI), the MCR during the OGTT was estimated by correcting the M value with MBG
during the 2-h test (MCR [mg ? l– 1 ? mmol ? l– 1 ? m i n– 1] = M/MBG). SI was then cal-
culated as MCR/log MSI during the OGTT. Thus, the SI value, as defined here, is an
approximate numerical index of the curve relating the MCR to the log of insulin dur-
ing clamp tests in a test where a constant OGL is given. In our hands, SI c a l c u l a t e d
from the OGTT correlated with SI calculated from the frequently sampled intra-
venous glucose tolerance test (FSIVGTT) with minimal model analysis (r = 0.72, P
< 0.0001, n = 46) (J.M.F.-R., W.R., R.C., unpublished observations).
Insulin resistance was also calculated through the fasting insulin resistance
index (FIRI). FIRI = fasting glucose (mmol/l) 3 fasting insulin (mU/l)/25. In our expe-
rience, FIRI fairly correlates with the SI calculated from FSIVGTT with minimal model
analysis (r = 0.79, P < 0.0001, n = 46) (J.M.F.-R., W.R., R.C., unpublished observations).
Analytical methods. The serum glucose level during the OGTT was measured
in duplicate by the glucose oxidase method with a glucose analyzer 2 (Beckman,
Brea, CA). The coefficient of variation (CV) was 1.9%. The serum insulin level was
measured in duplicate by monoclonal immunoradiometric assay (IRMA) (Med-
genix Diagnostics, Fleunes, Belgium). The lowest limit of detection was 4.0 mU/l.
The intra- and interassay CVs were 5.2 and 6.9%, respectively.
The Medgenix sTNF-R1 and sTNF-R2 solid-phase enzyme-amplified sensitiv-
ity immunoassays (EASIAs) (BioSource Europe, Fleunes, Belgium) were per-
formed on microtiter plate. The minimum detectable concentration was esti-
mated to be 0.1 ng/ml and was defined as the sTNFR1 or sTNFR2 concentration
corresponding to the average optical density of 20 replicates of the zero standard
+ 2 SDs. The intra- and interassay CVs were <7 and <9%. sTNFR1 EASIA does not
cross-react with sTNF-R2. TNF-a does not interfere with the assay.
Plasma TNF-a was measured using IRMA (Medgenix Diagnostics). Serum
creatine kinase (CK) activity was measured by standard routine assays through
the velocity of ATP synthesis when the enzyme is in contact with phosphocrea-
tine and ADP.
Total serum cholesterol was measured through the reaction of cholesterol
esterase/cholesterol oxidase/peroxidase (24). VLDL cholesterol was measured
after ultracentrifugation at 45,000g. HDL cholesterol was quantified after pre-
cipitation with polyethylene glycol at room temperature (25). Total serum
triglycerides were measured through the reaction of glycerol-phosphate-oxi-
dase and peroxidase (26). VLDL triglycerides were measured after ultracen-
trifugation at 45,000g. LDL cholesterol was calculated as total cholesterol –
(VLDL cholesterol + HDL cholesterol).
Statistical analyses. Descriptive results of continuous variables are expressed
as means ± SD. Non-Gaussian-distributed variables were log1 0 transformed to
achieve normality. This applied to fasting levels of insulin, FIRI, SI from the OGTT,
sTNFR1, and sTNFR2. Relationships between variables were sought by Pearson’s
correlation coefficient and stepwise multivariate linear regression analysis with for-
ward selection. The regression coefficient generated by this analysis indicates the
slope of the association between the dependent variable and the specified inde-
pendent variable, after adjusting for other independent variables in the model. The
SE represents the variability in this association, and the significance is refle c t e d
by the P value. Comparison of variables across lean and obese men and women
was performed by one-way analysis of variance using Fisher’s test for multiple com-
parisons. Levels of statistical significance were set at P < 0.05.
All these analyses were performed with the BMDP statistical package 
(BMD Statistical Software, Cork, Ireland).
R E S U LT S
Anthropometric and biochemical characteristics of the subjects
are shown in Table 1. Time since diagnosis of MyD had no effect
on any of the parameters measured. In our study sample, no
s i g n i ficant correlations between either sTNFR1 or sTNFR2
and BMI were found in either control subjects (r = 0.08 and r
= 0.29 [NS], respectively) or MyD patients (r = 0.24 [NS] and r
= 0.36 [P = 0.09], respectively). This is in contrast to previous
observations in subjects with significantly higher BMI (17,18)
or with a wider range of BMI than in this study sample (18). By
excluding subjects with higher BMI and sTNFR2 levels, we are
weakening the relationship between BMI and sTNFR2. In MyD
patients, the lack of association was due to disproportionately
increased sTNFR2 levels in patients with low BMI.
Both men and women MyD patients showed higher
plasma insulin levels than control subjects in the presence of
comparable glucose concentrations. sTNFR2, but not
sTNFR1, levels were ~1.5-fold higher in MyD patients (Table 1).
In parallel with these findings, FIRI was also higher in MyD
patients. In fact, in the whole population, fasting insulin and
FIRI strongly correlated with sTNFR2 in both men (r = 0.77
and r = 0.81, P < 0.0001, respectively) and women (r = 0.67
and r = 0.64, P = 0.001, respectively) (r = 0.57, P < 0.0001, in
all subjects) (Fig. 1). sTNFR2 levels were also associated
with the SI calculated from the OGTT (r = –0.43, P = 0.006)
(Fig. 2). We constructed a multiple linear regression model to
predict FIRI, with BMI, WHR, and sTNFR2 as independent
variables. In this model, both BMI (P = 0.0014) and sTNFR2
(P = 0.0048) levels contributed independently to 46% of the
variance of FIRI. In another model, in which FIRI was sub-
stituted for SI from the OGTT, both BMI (P = 0.0001) and
sTNFR2 (P = 0.04) levels contributed independently to 48%
of the variance of SI from the OGTT.
Plasma TNF-a levels were below the linear range of the
assay in 55% of the patients. This finding precludes a correct
interpretation of circulating TNF-a.
Plasma LDL cholesterol and triglyceride concentrations
were significantly increased in MyD patients (Table 1). How-
e v e r, it is important to note that LDL measurements were
inferred by subtraction, and this approach may not be accu-
rate given the elevated triglycerides. sTNFR1 and sTNFR2
FIG. 1. Linear correlation between circulating sTNFR2 levels and
FIRI (r = 0.57, P < 0.0001). d, MyD patients.
FIG. 2. Linear correlation between circulating sTNFR2 levels and SI
obtained from the OGTT in all subjects (r = –0.43, P = 0.006, n = 46).
d, MyD patients.
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levels were found to be strongly associated with plasma
cholesterol, LDL cholesterol, and triglycerides (Table 2).
Plasma sTNFR1 and sTNFR2 levels also correlated with
serum CK activity in MyD patients (r = 0.57 [P = 0.006] 
and r = 0.75 [P < 0.0001] for sTNFR1 and sTNFR2, respec-
tively) (Fig. 3).
D I S C U S S I O N
The correlation between fasting insulin, FIRI, the SI
obtained from the OGTT, and sTNFR2 suggests that both
glucose and sTNFR2 might be regulated by the same
related signal. In fact, increased expression of TNF-a
strongly correlates with the level of hyperinsulinemia (8)
and the glucose disposal rate during euglycemic clamp
technique (9). Because TNF-a is a strong inducer of TNFR2
expression in adipocytes (17) and other cell types (27),
the negative correlation between insulin sensitivity and
sTNFR2 might be attributed to increased TNF-a action in
situations of insulin resistance. Marked hyperinsulinemia
after OGTT is well known in MyD patients (3,4,28), and here
we describe, for the first time to our knowledge, a rela-
tionship between insulin action and plasma sTNFR2 con-
centration in MyD patients.
sTNFRs are present constitutively in serum at concentra-
tions that increase significantly in both inflammatory and
n o n i n flammatory disease states (29). TNFRs may in some sit-
uations inhibit the effects of TNF, in others, serve as carriers
for TNF, and in some cases they may even augment the
effects of TNF by prolonging its function (16). The study of
the mechanisms that control TNFR function will provide
new insights in the pathogenesis of insulin action in general
and in the etiology of insulin resistance in MyD.
Glucose transport and oxidation are decreased in adipose
tissue—the main metabolic target of TNF-a—in MyD
patients (30). A decreased phosphorylation of muscle sar-
colemma due to deficient PK activity in muscle obtained
from MyD patients has been described (31). Although this defi-
cient PK activity is probably of genetic origin (2), it will be
important to study whether these alterations in PK are ampli-
fied by increased TNF-a action (comparable to the reduction
in tyrosine kinase activity of the insulin receptor induced by 
T N F -a [10]). The association between sTNFRs and CK is in
concordance with the action of recombinant human TNF-a
in vivo, which yielded higher serum CK values after its intra-
venous administration in melanoma patients (32).
In the last years, it has been demonstrated that TNF-a h a s
important effects on whole-body lipid metabolism (33). TNF
actions are thought to cause hypertriglyceridemia due to
decreased lipolysis and increased VLDL secretion (33).
Hypertriglyceridemia is well described in patients with the
acquired immunodeficiency syndrome (34) or cystic fib r o s i s
(35), two states of inferred high TNF-a action. Here we
describe increased concentrations of plasma triglycerides
and cholesterol levels in parallel with sTNFR1 and sTNFR2
concentrations in MyD patients. Interestingly, proinsulin-
insulin hypersecretion has already been found to correlate
with the levels of cholesterol and triglyceride in MyD (36). We
speculate that this latter association is dependent on, and sec-
ondary to, increased TNF-a action. TNF-a has been found to
produce a 25% increase in serum cholesterol levels and a
2.3-fold increase in hepatic hydro-3-methyl-glutaryl CoA
reductase activity in C57Bl/6 mice (37). TNF-a is also capa-
ble of inducing sterol regulatory element binding protein-1
maturation, a key transcription factor in cholesterol biosyn-
thesis, in a time- and dose-dependent manner (38). In condi-
tions in which acute TNF secretion is not induced, increased
cholesterol levels might be the first event, with TNF hyper-
secretion being secondary to lipid derangement. In this
sense, the accumulation of cholesteryl esters in macro-
phages exposed to LDL immune complexes is associated
with increased synthesis and release of TNF-a ( 3 9 ) .
Increased TNF secretion has also been observed in hyperc-
holesterolemic rabbits (40) and in LDL receptor knockout
mice, in which plasma TNF-a levels are elevated in parallel
with LDL cholesterol (41). Furthermore, atherogenic diets
enhance endotoxin-stimulated TNF-a gene expression in
rabbit aortae (42). The implications of our findings are poten-
tially important in the sense that sTNFR1 and sTNFR2 could
constitute markers of atherosclerosis.
In summary, plasma sTNFR1 and sTNFR2 levels are asso-
ciated with several metabolic abnormalities in MyD
patients. Whether TNF action is implicated in the patho-
genesis of MyD or is a simple marker of disease activity
awaits further studies.
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TABLE 2
Correlation between sTNFR1, sTNFR2, and lipid parameters
C h o l e s t e r o l LDL cholesterol Tr i g l y c e r i d e s
s T N F R 1 0.58 (P < 0.001) 0.62 (P < 0.0001) 0.41 (P < 0.005)
s T N F R 2 0.60 (P < 0.0001) 0.65 (P < 0.0001) 0.59 (P < 0.0001)
FIG. 3. Linear correlations between circulating sTNFR2 levels and
serum CK in MyD patients (r = 0.75, P < 0.0001, n = 22).
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